Preventing heart attacks in middle-aged adults with early plaque
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether starting cholesterol-lowering treatment early can prevent heart attacks in people aged 30-50 who already have early signs of artery plaque but no history of heart disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 50 years old
- You have never had a heart attack, stroke, or blocked leg arteries
- Your LDL cholesterol is above 70 mg/dL
- You have early plaque in your arteries (seen on an ultrasound or CT scan) or a high lifetime risk of heart disease combined with risk factors like family history, diabetes, or smoking
- You are not pregnant, nursing, or planning to become pregnant without using effective birth control
- You do not have a serious illness like cancer, liver disease, or alcohol/drug abuse that would affect your ability to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a newer cholesterol-lowering injection, given early after a heart attack, helps keep the plaque in your arteries stable and reduces future risk. It compares the new medicine added to your usual statin treatment.
This trial tests if adding inclisiran to your current statin can reduce dangerous, rupture-prone plaque in your heart arteries. It may help if you have a moderate blockage with thin-cap plaque and your LDL cholesterol stays high despite statins.
This trial tests whether higher doses of cholesterol-lowering medication (statins) can slow down plaque buildup in the heart arteries of younger and middle-aged adults with stable chest pain. It may help prevent heart attacks and the need for procedures like stents.
This study tests whether giving a new cholesterol-lowering drug, inclisiran, early during a hospital stay after a heart attack can help lower bad cholesterol (LDL) more effectively than usual care. It may reduce the risk of future heart problems.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study tests a new injectable medicine called inclisiran for people who are already on many medications and have high cholesterol. It is designed for those who cannot lower their cholesterol enough with statins, especially if they have diabetes or other heart risks.
Hear when a new Atherosclerotic Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.